369 related articles for article (PubMed ID: 21292439)
1. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
2. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
5. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
6. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia.
Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL
Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507
[TBL] [Abstract][Full Text] [Related]
7. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
[TBL] [Abstract][Full Text] [Related]
8. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia.
Chang CY; Chabot P; Thomas JP
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976
[TBL] [Abstract][Full Text] [Related]
9. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
11. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
12. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
13. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
14. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia.
Roy N; Mauszycki SC; Merrill RM; Gouse M; Smith ME
Folia Phoniatr Logop; 2007; 59(2):83-90. PubMed ID: 17337898
[TBL] [Abstract][Full Text] [Related]
15. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia.
Adams SG; Hunt EJ; Irish JC; Charles DA; Lang AE; Durkin LC; Wong DL
J Otolaryngol; 1995 Dec; 24(6):345-51. PubMed ID: 8699600
[TBL] [Abstract][Full Text] [Related]
16. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
Adams SG; Hunt EJ; Charles DA; Lang AE
J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal variations of laryngeal overpressure and voice-related quality of life in spasmodic dysphonia.
Yeung JC; Fung K; Davis E; Rai SK; Day AM; Dzioba A; Bornbaum C; Doyle PC
Laryngoscope; 2015 Mar; 125(3):661-6. PubMed ID: 25290557
[TBL] [Abstract][Full Text] [Related]
18. Voice handicap index results for older patients with adductor spasmodic dysphonia.
Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
